Fannette Downie-Allman
Family Medicine · Fortuna, CANPI 1952597163
Payments from drug & device makers
Across 161 payments — averaging $15.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$589
- AstraZeneca$132
- AbbVie$120
- GSK$117
- Merck$88
- plus $400 from 15 others
What the payments were for
- Food & beverage$2,465100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 76 | $1,020 |
| Lilly USA, LLC | 41 | $589 |
| AstraZeneca | 8 | $132 |
| AbbVie | 6 | $120 |
| GSK | 3 | $117 |
| Merck | 5 | $88 |
| Mylan Specialty L.p. | 2 | $45 |
| Bayer | 2 | $40 |
| Idorsia Pharmaceuticals US Inc | 2 | $39 |
| Exact Sciences | 2 | $37 |
| Vertex | 2 | $36 |
| Biohaven Pharmaceuticals, Inc. | 2 | $34 |
| Pfizer | 2 | $27 |
| ANI Pharmaceuticals, Inc. | 1 | $26 |
| Amgen | 1 | $22 |
| Johnson & Johnson | 1 | $19 |
| Indivior Inc. | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
How this compares
$2,465 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 12 | $92,607 |
| OzempicSemaglutide | 74 | $64,149 |
| EliquisApixaban | 56 | $56,053 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 67 | $33,848 |
| JanuviaSitagliptin Phosphate | 33 | $33,116 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $24,879 |
| OxycontinOxycodone Hcl | 22 | $23,759 |
| TrulicityDulaglutide | 24 | $22,338 |
| FarxigaDapagliflozin Propanediol | 23 | $21,136 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 670 | $21,084 |
| XareltoRivaroxaban | 16 | $17,477 |
| EntrestoSacubitril/Valsartan | 20 | $16,715 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 16 | $16,127 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $13,816 |
| CreonLipase/Protease/Amylase | 12 | $10,968 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,020 | $64,14974 claims |
| GSKAnoro Ellipta, Trelegy Ellipta | $117 | $58,727103 claims |
| PfizerEliquis | $27 | $56,05356 claims |
| MerckJanuvia, Belsomra, Dulera | $88 | $44,75762 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere, Symbicort | $132 | $36,65062 claims |
| Lilly USA, LLCTrulicity | $589 | $22,33824 claims |
| Johnson & JohnsonXarelto | $19 | $17,47716 claims |
| AbbVieCreon | $120 | $10,96812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.
Other family medicine in Fortuna
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.